FINWIRES · TerminalLIVE
FINWIRES

$DD

7 stories mentioning DDUpdated just now

Every FINWIRES story that references DD, newest first.

What's the latest news on DD?

Equities

S&P 500 Index Slips Weekly as Health Care, Materials Weigh

The Standard & Poor's 500 index slipped 0.8% this week, led to the downside by the health care and materials sectors.The S&P 500 ended the week at 7,656.98. This is the index's first weekly decline since the week ended Aug. 21. It's now down 0.4% for September but up almost 12% this year.Data released Friday showed US consumer prices rose 0.4% month over month in August, the fastest pace since May and matching expectations. Core inflation, which excludes the more volatile food and energy components, jumped to a four-month high of 0.3%, exceeding market projections for an unchanged 0.2% growth.Expectations for a rate increase at the Federal Reserve's next Federal Open Market Committee meeting, which is set for next week, rose after the inflation report. Bets for the US central bank to increase its benchmark lending rate by 25 basis points next week jumped to 87% Friday from 72% Thursday, according to the CME FedWatch tool.US consumer sentiment weakened in September, while inflation expectations rose, with the year-ahead price growth outlook reaching the highest reading since June, preliminary results of a University of Michigan survey showed Friday.By sector, health care had the largest percentage drop of the week, falling 3.6%, followed by a 2.7% decline in materials. Industrials and utilities shed 1.7% each, financials fell 1.5%, consumer discretionary declined 1.2% and real estate slipped 1.1%. Consumer staples and technology also edged lower.Cooper (COO) led the decliners in health care and also had the largest percentage drop in the overall S&P 500 for the week, tumbling 23% amid weaker-than-expected fiscal Q3 sales. The company also lowered its full-year outlook.Corteva (CTVA) was among the decliners in the materials sector, slipping 4.5%. Chemours (CC), DuPont de Nemours (DD) and Corteva said they have agreed to a $455 million settlement with North Carolina and 11 local entities to resolve PFAS-related claims. Shares of Chemours and DuPont also declined on the week.Just two sectors rose as energy climbed 2% and communication services gained 1.1%.The energy sector's advance came as crude oil futures rose on the week. The White House is mulling ways it can use the Defense Production Act to expand US oil refining capacity, Reuters reported, citing two sources familiar with the plans. Saudi Arabia's Energy Ministry said on Friday its East-West pipeline was shut after multiple attacks, according to media reports.The energy sector's top gainers included Valero Energy (VLO), which rose 5.3%, and APA (APA), which climbed 4.6%.All eyes next week will be on the two-day FOMC meeting set to conclude on Wednesday. Economic data will include August retail sales, pending home sales, industrial production and capacity utilization.

Dow JonesNasdaq CompositeS&P 500$APA$CC$COO$CTVA$DD$VLO
Stocks Rise Pre-Bell Ahead of Latest Round of Earnings; Investors Gauge Uncertainty Over Potential US-Iran Deal
US Markets

Stocks Rise Pre-Bell Ahead of Latest Round of Earnings; Investors Gauge Uncertainty Over Potential US-Iran Deal

US equity futures were tracking in the green on Tuesday as traders await the latest batch of corporate earnings and assess ongoing uncertainty over a potential resolution to the Middle East conflict.The S&P 500 rose 0.2% in premarket activity, while the Dow Jones Industrial Average and the Nasdaq gained 0.3% each. All three main indexes finished Monday trading up, with the Dow notching a record closing high.Caterpillar (CAT), Merck (MRK), McDonald's (MCD), Pfizer (PFE), Spotify Technology (SPOT), Transdigm (TDG), Rockwell Automation (ROK), Archer-Daniels-Midland (ADM), Kimberly-Clark (KMB), BioNTech (BNTX) and DuPont de Nemours (DD) are all scheduled to report their latest financial results before the bell.SpaceX (SPCX) shares were up 2% pre-bell with the rocket and satellite company expected to release its first quarterly results since going public after the markets close, along with Advanced Micro Devices (AMD), Arista Networks (ANET), Amgen (AMGN) and Gilead Sciences (GILD).Palantir Technologies' (PLTR) stock jumped 15% early Tuesday as the company lifted its full-year revenue guidance on the back of stronger-than-expected second-quarter results. Snap (SNAP) climbed 7.3% after the social media company announced second-quarter results above Wall Street's estimates.President Donald Trump reportedly said Monday that the latest round of talks between the US and Iran is the "last chance" for Tehran to "sign a good document." Trump recently called off a planned attack on Iran.However, Iranian Foreign Ministry spokesperson Esmail Baghaei reportedly ruled out an immediate plan to negotiate with Washington. Tehran was in talks with Oman regarding the Strait of Hormuz, the world's most important chokepoint for crude flows, Baghaei reportedly said.West Texas Intermediate crude oil inclined 1.6% to $81.64 a barrel before the opening bell, while Brent advanced 2.3% to $85.66."Hopes of a peace deal in the Middle East weighed on crude prices," D.A. Davidson said in a Monday client note.Treasury yields were trending higher in premarket action, with the two-year rate ticking up 1 basis point to 4.27% and the 10-year rate adding 2.2 basis points to 4.71%.Tuesday's economic calendar has the international trade in goods and services report for June at 8:30 am ET, followed by the Job Openings and Labor Turnover Survey for the same month at 10 am.Gold moved up 0.3% to $4,103 per troy ounce, while bitcoin declined 0.7% to $63,441.

Dow JonesNasdaq CompositeS&P 500$ADM$AMD$AMGN$ANET$BNTX$CAT$DD$GILD$KMB$MCD$MRK$PFE$ROK$SPCX$SPGI$SPOT$TDG
Wire

3M, DuPont, Corteva, Chemours Sued by New York AG Over Toxic Pollution From Consumer Products

3M (MMM), EIDP, Chemours Co. (CC), Corteva (CTVA) and DuPont de Nemours (DD) are facing a New York State lawsuit alleging that they knowingly sold toxic polyfluoroalkyl substances -- so-called forever chemicals or PFAS -- used in a range of consumer goods.New York Attorney General Letitia James said Thursday that the chemical manufacturers produced and sold the materials despite knowing their toxicity while actively hiding environmental and health hazards from the public.Company data allegedly showed that 3M found the substances in human blood during the 1970s, while DuPont allegedly suppressed 1981 research linking the products to birth defects in exposed pregnant employees, according to the AG statement.The state is seeking a court order to establish corporate liability, force the businesses to finance environmental remediation, and secure monetary restitution alongside other penalties, the statement added.3M, EIDP, Chemours, Corteva, DuPont de Nemours did not immediately respond to' requests for comment.Price: $156.72, Change: $+2.02, Percent Change: +1.31%

$CC$CTVA$DD$MMM
Wire

Street Color: 3M, Chemours Among Firms Sued by New York Attorney General Over Alleged PFAS Pollution

Street Color: 3M, Chemours Among Firms Sued by New York Attorney General Over Alleged PFAS Pollution

$CC$CTVA$DD$MMM
Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Dupont De Nemours, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $57, valuing DD shares at 22x our 2027 EPS estimate of $2.60 (raised by $0.11) and 24x our 2026 EPS estimate of $2.35 (raised by $0.07). Our target multiples compare to DD's three-year average forward multiple of 19x. DuPont reported impressive Q1 2026 results with adjusted EPS of $0.55 versus $0.36 in the prior year, beating consensus estimates of $0.48, while net sales rose 4% (beating our 3% forecast) with organic growth of 2% and operating EBITDA margins that expanded 230 bps to 24.6% from 22.3%. Operating cash flow more than tripled to $232M from $77M, and transaction-adjusted free cash flow surged to $147M from $8M Y/Y, with operating EBITDA rising 15% to $414M. We applaud these results, as DuPont delivered strong performance across all metrics while completing its strategic portfolio transformation, demonstrating pricing power with a 1% pricing contribution and significant margin expansion despite mixed end-market conditions.

$DD
Wire

DuPont's Earnings Growth Holds Up Despite Iran-Linked Headwinds, RBC Says

DuPont de Nemours (DD) continues to post solid earnings growth as cost-optimization efforts and stronger volumes in key end markets counter weakness in the building and construction segment and higher expenses tied to the Iran conflict, RBC Capital Markets said Friday in a report.Most near-term headwinds stem from the Middle East conflict, and DuPont expects $90 million in cost pressure, while the company plans to recover earnings through price increases and customer surcharges, the report said.Softness in building and construction is weighing on the building technologies division, and DuPont expects low single-digit organic sales growth in Q2 and the full year, the report said.Given H1 and full-year guidance, RBC said it does not expect a material margin step-up in H2. Even so, projections indicate H2 EPS of $1.23, compared with $1.15 in H1, the report said.RBC cut its Q2 EPS estimate to $0.59 from $0.61 while boosting forecasts to $2.41 from $2.23 in 2026 and to $2.69 from $2.59 in 2027.RBC raised its price target on DuPont stock to $60 from $56 and maintained its outperform rating.Price: $50.70, Change: $+0.94, Percent Change: +1.89%

$DD
Research

Research Alert: Dupont Q1 Eps Tops Expectations; Margins And Cash Flow Surge

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:DuPont reported impressive Q1 2026 results with adjusted EPS of $0.55 versus $0.36 in the prior year, beating consensus estimates of $0.48, while net sales rose 4% (beating our 3% forecast) with organic growth of 2% and operating EBITDA margins that expanded 230 bps to 24.6% from 22.3%. Operating cash flow more than tripled to $232M from $77M, and transaction-adjusted free cash flow surged to $147M from $8M year-over-year, with operating EBITDA rising 15% to $414M. We applaud these results, as DuPont delivered strong performance across all metrics while completing its strategic portfolio transformation demonstrating pricing power with a 1% pricing contribution and significant margin expansion despite mixed end-market conditions. With the Aramids divestiture now closed and $1.8B of proceeds in hand, management is well-positioned to accelerate shareholder returns while investing in its higher-margin Healthcare and Water Technologies businesses.

$DD

Track with the FINWIRES app suite